With Finance Minister Nirmala Sitharaman set to present the Union Budget for FY 2025-26 on February 1, investors are closely ...

Since markets tend to see a drop in volatility rather than a clear directional move, traders may find volatility-based strategies more effective than simple buy-or-sell approaches.

Joe McCarthy from Elston and David Wilson from First Sentier run the ruler over your most-tipped growth stocks for 2025 ...

The ACA marketplace at HealthCare.gov is a great way to find health insurance if you can’t get coverage through work. Our ratings take into account a product's cost, features, ease of use ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Alterity Therapeutics ATHE shares moved upwards by 95.9% to $5.7 during Thursday's pre-market session. The market value of their outstanding shares is at $49.8 million. T ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we are going to take a look at where UnitedHealth Group Incorporated ...

Cigna has deleveraged substantially after acquiring Express Scripts in late 2018 when Cigna's debt rose to over $42 billion, or debt/capital of 51%. Management has made good progress on its ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

While RFK Jr. is likely to lead the Department of HHS, he will be limited in his ability to stop the continued innovation and ...

WisdomTree U.S. SmallCap Dividend Fund offers a 2.8% yield but underperforms peers, with a sector allocation impacting growth potential. Learn more on DES stock here.

In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...